Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study (BMC Cardiovascular Disorders, 2022)

(untitled) - Wechalekar, A; Antoni, G; Al Azzam, W; Bergström, M; Biswas, S; Chen, C; Cheriyan, J; Cleveland, M; Cookson, L; Galette, P; Janiczek, RL; Kwong, RY; et al.